The compnay said that the private placement has been launched without preferential subscription rights, to qualified investors, pursuant to the eighth resolution of the Combined General Shareholders Meeting held on 3 June 2015, in the amount of approximately €6 million, i.e. approximately 10% of the Company’s share capital. Application will be made for the new shares to be admitted for trading on Euronext Paris.

The funds will be raised in accordance with Article L.411-2 II of the French Monetary and Financial Code (Code monétaire et financier) (the "Private Placement"), from domestic and international qualified investors, notably excluding Canada, Australia and Japan. They will be used to further the development of the isobutene process and to launch commercial roll-out.

The CM-CIC Investissement SCR and CM-CIC Innovation funds have undertaken, under certain conditions, to subscribe to the capital increase for a total of 18% of the funds to be raised, in an amount not to exceed €1.8 million, and at a maximum price of €25.5 per share. The FCPIs BioSanté 2013, BioSanté 2014, Masseran Innovation VI and Seventure Preference Innovation 2013
high-tech mutual funds have undertaken, under certain conditions, to subscribe to the capital increase for a total amount of €1.7 million, at a maximum price of €25.5 per share.

According to the terms of the eighth resolution of the Combined General Shareholders Meeting held on 3 June 2015, the issue price of the new shares will be at least equal to the weighted average price of the Company’s share on the Euronext Paris Alternext market in the last three trading sessions prior to setting the issue price, which may be reduced by a maximum discount of 20%, within the limit of 17,5% of the Company’s share capital, i.e. a maximum of 504 039 new shares.

Marc Delcourt, CEO at Global Bioenergies says: "The funds raised through this private placement will enable the Company to switch to full-scale commercial roll-out. We are expecting to sign several significant industrial agreements starting in 2016."

The Private Placement is being conducted by Gilbert Dupont (Paris) and Baader Bank AG (Munich) as joint lead managers and joint bookrunners. The issue does not require registration with the French financial markets authority (AMF) or publication of a prospectus.

The final terms and results of the Private Placement will be announced as soon as possible.